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Intensive Interferon Therapy Does Not Increase
Virological Response Rates in African
Americans with Chronic Hepatitis C
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To determine if an intensive regimen of daily, high-dose interferon would improve the initial response
rates to therapy for hepatitis C genotype 1 among African American and Caucasian patients, we
conducted a retrospective analysis of a treatment trial conducted between October 1995 and June
1997. Patients were randomized to 24 weeks of therapy with interferon−α-2b at either 5 MUdaily
or 3 MU three times a week. On the standard interferon regimen (3 MU three times a week) African
Americans and Caucasians had similar initial response rates. However, unlike Caucasians, African
Americans did not have an increased initial virological response when treated with an intensive,
daily dose regimen. Levels of HCV RNA decreased more slowly during the first 12 weeks of therapy
among African Americans. Nelson-Aalen cumulative hazard estimates for the different race and dose
combinations revealed that Caucasians who received daily interferon were most likely to have an
initial response (logrank,P < 0.001).
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Major advances have been made over the last decade in the
field of antiviral therapy for chronic hepatitis C. Combi-
nation therapy with interferon and ribavirin has improved
virological sustained response rates to nearly 40% com-
pared to only 10–15% for patients treated with interferon
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alone. Unfortunately, response to therapy is not uniformly
favorable and, undoubtedly, involves a complex interac-
tion between host and viral elements.
Recent evidence has suggested that race and ethnicity
may modify the likelihood of achieving a sustained viro-
logical response to interferon therapy (1–4). Reddy et al
(1) reported that end-of-treatment and sustained virolog-
ical responses were lower in black subjects compared to
white subjects treated with consensus interferon at stan-
dard doses. Of 40 black subjects, only two (5%) had HCV
RNA levels below detectable limits, as compared to 127
of 380 (33%) white subjects at the end of treatment. Sus-
tained virological response occurred in only one of these
black subjects (2%) while 12% (46/380) of white subjects
remained negative for HCV RNA six months after treat-
ment. Similar results were obtained when the data were
limited to subjects with genotype 1, with the exception
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that sustained virological response was virtually identical
for blacks and whites (3% vs 7%). In that study, median
HCV RNA levels also decreased to a lesser extent in black
subjects than in white subjects, and the mean change in
HCV RNA levels during the course of therapy tended to
be smaller in blacks (1). Thus, although race was corre-
lated with decreases in HCV RNA levels during therapy in
a logistic multiple regression model controlling for race,
gender, baseline HCV RNA level, and genotype, the au-
thors failed to demonstrate that race was associated with
sustained virological response.
McHutchison et al performed a retrospective analysis
of data from two large multicenter trials of interferon
monotherapy versus interferon and ribavirin combination
therapy for the treatment of chronic HCV (2). Subjects
were treated with interferon monotherapy 3 MU thrice
weekly or interferon and ribavirin combination therapy
for either 24 or 48 weeks. Of 1744 subjects who were
randomized and received treatment, only 53 (2.6%) sub-
jects were black, but the data corroborate the findings
of other investigators. No black participants responded
to interferon monotherapy, while 88 of 675 (13%) white
participants achieved a sustained virologic response. In
addition, black subjects had significantly smaller reduc-
tion in HCV RNA levels during therapy compared to
whites. This difference was most apparent in black sub-
jects with genotype 1 infection who received interferon
monotherapy.
To date, patients in these studies have all been treated
with similar regimens of interferon (3 MU three times a
week or 9µg three times a week) alone or in combina-
tion with ribavirin. It is not known if a more aggressive
interferon regimen would improve response rates among
African Americans. We have previously reported that
treatment with daily, high-dose interferon significantly
improves initial and end-treatment response rates com-
pared to standard doses of thrice weekly interferon. We
conducted a retrospective analysis of our database, which
included a high percentage of African Americans, to deter-
mine if an intensive regimen of daily, high dose interferon
would improve the initial response rates to therapy for
hepatitis C among African American patients compared
to Caucasian patients.
MATERIALS AND METHODS
Details concerning study design and randomization have been
reported previously (5). Briefly, subjects were eligible for par-
ticipation if they had serologic evidence of hepatitis C, serum
alanine aminotransferase activity>1.3 times the upper limit of
normal, and detectable HCV RNA in serum by polymerase chain
reaction. Subjects were evaluated for other causes of liver disease
by appropriate serological screening and excluded from partici-
pation in the study if any such causes were identified. Subjects
who had previously received interferon were excluded. Based
upon earlier studies demonstrating that cirrhosis was an inde-
pendent predictor of poor response to interferon, subjects with
cirrhosis on a pretreatment liver biopsy were excluded. Likewise,
subjects who tested positive for antibody to human immunode-
ficiency virus were excluded.
Between October 1995 and June 1997, one hundred four sub-
jects were randomized to 24 weeks of therapy with interferon
−α-2b at either 5 MUdailyor 3 MU three times a week with an ad-
ditional 24-week period of posttreatment observation. Treatment
groups were prospectively stratified by HCV genotype (1 or non-
1) and pretreatment HCV RNA levels (<or>500,000 copies/ml)
(Figure 1). Treatment was discontinued at week 12 of therapy for
patients who remained HCV RNA positive, based upon recom-
mendations concerning the predictability of sustained response
at that time point for interferon monotherapy (6).
The study was conducted at eight referral centers in the United
States. The protocol was approved by the human investigations
committees at each participating institution. Written informed
consent was obtained from each subject prior to enrolment in
the study.
Nucleic Acid Analysis. Serum HCV RNA was analyzed using
the Amplicor Monitor (version 1.0) assay (Roche Molecular Sys-
tems, Branchburg, New Jersey, USA). The linear dynamic range
for this assay is 1× 103–1× 106 copies/ml. The lower limit of
quantitation of HCV RNA was 2000 copies/ml. HCV RNA levels
<1000 copies/ml were considered to be negative. HCV genotype
was determined by the line probe assay (InnoLiPa, Innogenetics,
Gent, Belgium).
Statistical Analysis. This analysis was limited to the sub-
set of 74 African American and Caucasian subjects with HCV
genotype 1. Stata (Stata Statistical Software: Release 6.0, 1999,
Stata Corporation, College Station, Texas, USA) was used for
all calculations. All data were analyzed by intention to treat.
Theχ2 test was used to compare qualitative variables (or two-
tailed Fisher’s exact test when some expected values were<5)
and Student’st test was used to compare means. Differences be-
tween groups for whichP ≤ 0.05 were considered statistically
Fig 1. Study schema: Subjects were stratified by baseline HCV
viral load and viral genotype.
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significant. All 74 subjects were included in the survival analy-
ses. The failure event was defined as having an HCV RNA that
was below the limits of detection by week 12. Subjects were
considered at risk once interferon therapy was initiated. The cut-
off point for the analysis was the last date for which data were
available for the subject. All subjects who had a virologic re-
sponse had data available at their week 12 visit. Participants
who were lost to follow-up were censored at the last date for
which data were available. Subjects who had a virologic re-
sponse but relapsed before week 12 were coded as if they had
never experienced a response. The date of each subject visit was
recorded and the unit of time for survival analysis was measured
in days. All explanatory variables were measured before the time
origin. There were no missing values among the explanatory
variables.
RESULTS
Of the 104 study participants from the parent study,
African Americans numbered 21 (20%) and Caucasians
78 (75%). Genotype 1 was significantly more common
among African Americans than Caucasians [20/21 (95%)
vs 54/78 (69%);P < 0.02]. The baseline demographic
characteristics of the subjects in the retrospective cohort
are presented in Table 1. There were no statistically sig-
nificant differences between African American subjects
with respect to mean age, gender distribution, and likeli-
hood of receiving treatment with interferon 5 MU daily.
African American subjects in the parent study were more
likely to be classified in the high-viral-burden group than
Caucasian subjects, but among African American and
Caucasian participants with genotype 1, mean levels of
HCV RNA were similar at baseline between the two racial
groups (1.37× 106 vs 6.38× 106, P = NS).
The response rates at week 12 among African Amer-
icans or Caucasians for two IFN regimens are shown
in Table 2. Thirty percent (9/30) of non-Hispanic white
patients had an initial response (defined as undetectable
HCV RNA at week 12 of treatment) when treated with the
standard interferon regimen of 3 MU three times a week
compared to 8% (1/12) of African Americans (P = NS).
However, with the more intensive, daily interferon regi-
men, white subjects were more likely than black subjects
to show an initial response (75% vs 25%,P = 0.03). Fur-
thermore, Caucasian subjects who received the more in-
tensive interferon regimen had a significantly better initial
TABLE 1. DEMOGRAPHIC ANDVIROLOGIC CHARACTERISTICS
AT BASELINE
African American Caucasian
(N = 20) (N = 54) P
Age (yr) 45± 9 42± 7 NS
Male gender 12 (60%) 35 (65%) NS
Interferon 5 MU 8 (40%) 24 (44%) NS
TABLE 2. INITIAL RESPONSE TOTWO INTERFERONDOSAGEREGIMENS
IN AFRICAN AMERICAN OR NON-HISPANIC WHITE PATIENTS WITH
GENOTYPE1
Initial Response [N (%)]
Interferon African Non-Hispanic
dose group American white P
5 MU daily 2/8 (25%)a 18/24 (75%)b 0.03 (a vs b)
3 MU (3×/week) 1/12 (8%)c 9/30 (30%)d NS (c vs d)
P NS (a vs c) <0.002 (b vs d)
response to therapy than did Caucasians treated with the
standard interferon dosing (75% vs 30%,P < 0.002). In
contrast, a more intensive regimen did not improve the
initial response among African American subjects (25%
vs 8%,P = NS).
The proportion of subjects with an undetectable HCV
viral load was evaluated at each study visit. The percent
of subjects with a viral load below the limits of detection
was stratified by race and dose of interferon and plotted
against time (Figure 2). At each visit beyond the week 2
visit, the proportion of Caucasian subjects with an unde-
tectable HCV RNA was greater than comparable African
American subjects, although the difference did not reach
statistical significance until the week 12 visit, and only in
the intensive treatment groups (P = 0.03).
The changes in geometric mean levels of HCV RNA
at various times among African Americans and Cau-
casians treated with either interferon regimen are shown in
Figure 3. The initial response to therapy was significantly
greater for Caucasians treated with intensive interferon
compared to either African American group or for white
subjects treated with standard interferon.
To determine whether or not time to becoming and stay-
ing HCV RNA negative was different between African
Fig 2. Proportion of African American and non-Hispanic white subjects
with an undetectable HCV RNA during the initial 12 weeks of treatment.
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Fig 3. Serial changes of HCV RNA during the initial 12 weeks of treat-
ment for each race/dose group. They axis shows the log10 geometric
mean copies per milliliter for HCV RNA.
Americans and Caucasians, we carried out a survival anal-
ysis using all 74 subjects. There were 30 failures (those
reaching the end point of negative HCV RNA in serum).
The total time at risk was 4930 days. Twenty-fivepercent
of subjects had achieved a virologic response by 56
days. The Nelson-Aalen cumulative hazard estimates are
graphically presented for each race and dose combination
(Figure 4). African Americans receiving standard doses
of interferon appeared to have the worst response, while
Caucasian subjects receiving high dose intensive therapy
seemed to respond the best. Caucasians allocated to the
standard interferon regimen and African Americans on the
intensive daily regimen had an intermediate response. We
compared the survival probabilities of the different race
Fig 4. Nelson-Aalen cumulative hazard estimates of the likelihood of
achieving an undetectable HCV RNA by week 12 of therapy. NHW=
non-Hispanic white; AA= African American; 3MU= Interferon 3MU
three times a week; 5MU= interferon 5MU daily.
and dose combinations and found that they were statisti-
cally different (logrank,P < 0.001).
Univariate analysis of explanatory variables was con-
ducted to explore correlates of virologic response by week
12. We examined five binary variables (race, interferon
dose, past alcohol use, gender, pretreatment viral burden)
using the logrank test. Viral burden was dichotomizeda
priori in the parent study. Subjects with HCV RNA lev-
els<500,000 copies/ml were considered to have a low
viral burden (3). All other subjects were classified in the
high-viral-load group. Age was analyzed as a continuous
variable using univariate Cox regression. We also analyzed
site of treatment as a categorical variable using the gen-
eralized Wilcoxon test of Breslow. Caucasians were more
likely to respond to interferon than African American sub-
jects (P < 0.03). Likewise, subjects allocated to the more
intensive interferon regimen were more likely to have an
initial virologic response than subjects treated with stan-
dard thrice-weekly interferon injections (P < 0.001). We
also evaluated dose by race. The more intensive regimen
was more effective than the standard regimen among Cau-
casian subjects (P < 0.01) but not among African Amer-
ican subjects, although there were fewer subjects in the
African American stratum. Past alcohol use and gender
were not associated with virologic response by week 12.
Low viral burden, on the other hand, was a predictor of
response (P < 0.01). Age was not found to be a signifi-
cant correlate of response. Treatment sites did vary with
respect to initial virologic outcome, but this did not reach
statistical significance (P = 0.06).
We subsequently specified a multivariate Cox propor-
tional hazards model using all the covariates evaluated in
our univariate analysis. We included these variables be-
cause they have been reported in the medical literature as
potential predictors of response. Site was included based
on the results of the univariate analysis. The model was
reduced by removing the most disputable covariates (treat-
ment site, past alcohol consumption, age) and rerunning
the model with the remaining variables. The likelihood ra-
tio test confirmed that the variables eliminated did not con-
tribute significantly to the model. The proportional haz-
ards assumption was evaluated graphically and found to
be appropriate. The exponentiated final model is presented
in Table 3. The model shows that the likelihood of achiev-
ing and maintaining a virologic response by week 12 of
therapy is twice as great (P < 0.01) for subjects receiving
intensive interferon therapy compared to subjects on stan-
dard interferon, controlling for the effects of race, gender,
and pretreatment viral burden. While African American
subjects and men appeared to fare worse than Caucasians
and women, respectively, these findings were not statisti-
cally significant. Controlling for the contributions of race,
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TABLE 3. RELATIVE HAZARDS (RH) OF INITIAL VIROLOGIC RESPONSE
AND 95% CONFIDENCEINTERVAL FROM COX PROPORTIONAL
HAZARDS MODEL
Model covariate RH (95% CI) P
Race 0.333 (0.099–1.123) 0.076
Dose 1.998 (1.352–2.954) 0.001
Gender 0.496 (0.240–1.025) 0.058
Pretreatment viral load 2.726 (1.293–5.750) 0.008
dose, and gender, the likelihood of a virologic response
was almost three times greater for subjects with a low
pretreatment viral load compared to participants with a
high HCV RNA (P < 0.01).
A sustained virologic response (measured 24 weeks af-
ter cessation of therapy) was seen in only one African
American patient (11%) treated with the high-dose reg-
imen compared to none in the standard-dose regimen.
In Caucasian patients treated with high-dose interferon,
10% had a sustained virologic response compared to 4%
of those on the standard regimen. These differences were
not statistically significant.
Adverse events have been previously described in detail
(5). Interferon was well tolerated in both the high-dose reg-
imen and the standard-dose regimen. Individual adverse
events occurred too infrequently to allow for meaningful
comparisons, but overall there was no difference in ad-
verse events between African American and Caucasian
participants (data not shown).
DISCUSSION
Recent secondary analyses of large databases derived
from clinical trials of various antiviral agents have sug-
gested that there may be racial disparities in response to
therapy for hepatitis C. Sustained response rates in African
American patients appear to be significantly lower than
in Caucasian patients treated with the same regimens.
However, these trials were not designed specifically to test
the hypothesis that race was a factor in response to ther-
apy, and very few African Americans have been included
as study subjects in all of the published registration trials
of antiviral agents for this disease. While the current study
also was not prospectively designed for this, the trial con-
tained a high proportion of African American subjects,
which closely mirrors the proportion of individuals with
hepatitis C who are African American (3).
Previously published reports that evaluated race and re-
sponse to interferon therapy have all utilized standard in-
terferon dosing regimens (3MU three times a week or 9µg
three times a week) (4, 7). From studies of viral kinetics af-
ter a single injection of interferon in patients with genotype
1, higher doses of interferon (5–15 MU) did result in more
rapid, greater decreases of HCV RNA when compared to
a standard dose of interferon (8–10). Thus, it is possible
that patients with characteristics of interferon resistance
might respond better to a more aggressive interferon regi-
men (11). Kinzie et al (12) used a dose escalation strategy
in which subjects without an early virological response
after 12 weeks of interferon were either dose-escalated
to 5 MU three times a week or continued at 3 MU three
times a week. They found that African Americans were
less likely to achieve an end of treatment response com-
pared to Caucasians. The more intensive treatment used
in the current study, which prospectively randomized pa-
tients to a daily, high dose regimen or a standard regimen,
provided an opportunity to test the relationship between
dose and response across racial groups.
The results of the current study corroborate reports that
African American patients with hepatitis C were more
likely to be infected with treatment resistant genotype 1
than were non-Hispanic whites (1, 2, 13, 14). Our analysis
of antiviral response was limited to only those patients,
African American or white, that had HCV genotype 1,
thus eliminating this potentially confounding variable.
The results presented here demonstrate that an intensive
regimen of daily high dose interferon is superior to stan-
dard interferon with respect to the proportion of subjects
who have an initial virologic response and with respect to
time to achieving such a virologic response. Of note, we
were able to show a dose response to interferon among
Caucasian participants, but no such effect was demonstra-
ble among African American subjects.
Because of its retrospective nature, it is worth noting
some limitations of the current study. Although we did
prospectively stratify subjects on the basis of low or high-
viralburden, we did not stratify by race. This may ex-
plain why African American subjects were more likely
than Caucasian subjects to be classified in the high-viral-
burden group. However, when we limited the data to the
subgroup of African American and Caucasian subjects
with genotype 1, the mean HCV viral load at baseline was
similar. We did not specifically inquire about adherence to
medications, nor did we include body mass index, base-
line weight, or pretreatment liver histology in our study.
In other published investigations, the contribution of these
factors to interferon response rates has been inconclusive.
Thus, the extent to which these potential confounders help
to explain the differences observed in this study between
African American and Caucasian patients with genotype
1 cannot be determined.
Another limitation of the study is based on the clas-
sification of subjects by race (15–18). Because race is
primarily a social construct, it is possible that observed
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differences between African American and Caucasian
subjects are behavioral and environmental in nature, rather
than being intrinsic to being African American or Cau-
casian. Race in this sense may merely be a surrogate for
something that we have failed to measure or adequately
control for in our analyses. Although the proportion
of African American subjects in this study is reflec-
tive of the percentage of HCV patients who are African
Americans, the total sample size may have been inade-
quately powered to show small but clinically significant
differences.
Despite these limitations, this is the first study to exam-
ine whether or not a significantly more intensive interferon
regimen would improve response rates in African Ameri-
cans. Treatment with a daily high-dose regimen improved
the initial response for Caucasians but had little effect on
response in African Americans. Thus, it appears that in-
creasing the dose and frequency of interferon does not
overcome the antiviral resistance in African Americans.
This may be of immediate relevance because the phar-
macokinetics of pegylated interferons mirrors in some
respects the daily high-dose interferon regimen used in
the current study. The data suggest that African Ameri-
can patients may have resistance to interferon that may
be incompletely overcome by the use of pegylated inter-
ferons. Indeed, preliminary reports suggest that the viro-
logical response in African Americans is improved with
pegylated interferon monotherapy but remains less than
that in Caucasian subjects (19, 20). Future studies should
carefully and prospectively evaluate the effect of race on
response to antiviral treatment for chronic HCV and in-
vestigate potential mechanisms for diminished response to
interferon.
ACKNOWLEDGMENTS
We thank Drs. William C Miller and Marcia Hobbs for their
review of the manuscript.
REFERENCES
1. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote
EJ, Albert D, Joh T: Racial differences in responses to therapy with
interferon in chronic hepatitis C. Consensus Interferon Study Group.
Hepatology 30:787–793, 1999
2. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE,
Dienstag J, Morgan T, Yao R, Albrecht J: The impact of in-
terferon plus ribavirin on response to therapy in black pa-
tients with chronic hepatitis C. Gastroenterology 119:1317–1323,
2000
3. Howell C, Jeffers L, Hoofnagle JH: Hepatitis C in African Amer-
icans: Summary of a workshop. Gastroenterology 119:1385–1396,
2000
4. Kimball P, Elswick RK, Shiffman M: Ethnicity and cytokine produc-
tion gauge response of patients with hepatitis C to interferon-alpha
therapy. J Med Virol 65:510–516, 2001
5. Fried MW, Shiffman ML, Sterling RK, Weinstein J, Crippin J,
Garcia G, Wright TL, Conjeevaram HS, Reddy KR, Peter J, Cotso-
nis GA, Nolte FS: A multicenter, randomized trial of daily high-dose
interferon-alfa 2b for the treatment of chronic hepatitis C: pretreat-
ment stratification by viral burden and genotype. Am J Gastroenterol
95:3225–3229, 2000
6. Fried MW: Advances in therapy for chronic hepatitis C. Clin Liver
Dis 5:1009–1023, 2001
7. Shiffman ML: Use of high-dose interferon in the treatment of chronic
hepatitis C. Semin Liver Dis 19 (suppl 1):25–33, 1999
8. Layden TJ, Lam NP, Wiley TE: Hepatitis C viral dynamics. Clin
Liver Dis 3:793–810, 1999
9. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden
TJ, Perelson AS: Hepatitis C viral dynamicsn vivoand the antiviral
efficacy of interferon-alpha therapy. Science 282:103–107, 1998
10. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden
TJ: Dose-dependent acute clearance of hepatitis C genotype 1 virus
with interferon alfa. Hepatology 26:226–231, 1997
11. Bekkering FC, Brouwer JT, Leroux-Roels G, Van Vlierberghe H,
Elewaut A, Schalm SW: Ultrarapid hepatitis C virus clearance by
daily high-dose interferon in nonresponders to standard therapy. J
Hepatol 28:960–964, 1998
12. Kinzie JL, Naylor PH, Nathani MG, Peleman RR, Ehrinpreis MN,
Lybik M, Turner JR, Janisse JJ, Massanari M, Mutchnick MG:
African Americans with genotype 1 treated with interferon for
chronic hepatitis C have a lower end of treatment response than
Caucasians. J Viral Hepat 8:264–269, 2001
13. Wiley TE, Mika BP, McCarthy ME, Layden TJ: Pre-treatment dif-
ferences between HCV-infected African American and non-African
American patients. Hepatology 30:265A, 1999
14. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F,
Moyer LA, Kaslow RA, Margolis HS: The prevalence of hepatitis
C virus infection in the United States, 1988 through 1994. N Engl J
Med 341:556–562, 1999
15. Kaufman JS, Cooper RS: Commentary: considerations for use of
racial/ethnic classification in etiologic research. Am J Epidemiol
154:291–298, 2001
16. Cooper RS, Freeman VL: Limitations in the use of race in the study
of disease causation. J Natl Med Assoc 91:379–383, 1999
17. Witzig R: The medicalization of race: scientific legitimization of a
flawed social construct. Ann Intern Med 125:675–679, 1996
18. Senior PA, Bhopal R: Ethnicity as a variable in epidemiological
research. BMJ 309:327–330, 1994
19. Lindsay KL, McHutchison JG, Ling M-H, Albrecht JK: Response
to PEG-IFN a2b (PEG-Intron) in blacks and hispanics with HCV
is higher than with standard IFN a2b (IFN). Hepatology 32:347A,
2000
20. Shiffman ML, Fromm H, Mills P, Moonka Dk, Fried MW, Berg
C, Sherman M, Coleman S, Marsano LS, Reddy KR, Brunda MJ,
De Pamphilis J: Enhanced efficacy of pegylated (40kda) interferon
alfa-2a (Pegasys) compared with interferon alfa-2a (Roferon-A) for
chronic hepatitis C in blacks. Hepatology 32:348A, 2000
Digestive Diseases and Sciences, Vol. 48, No. 1 (January 2003) 145
